February 10, 2017

A new study from Karolinska Institutet shows that short-course preoperative radiotherapy combined with delayed surgery reduces the adverse side-effects of rectal cancer surgery without compromising its efficacy. The results are presented in the journal The Lancet Oncology.

Rectal cancer affects some 2,000 men and women in Sweden every year. Preoperative radiotherapy was gradually introduced in the early 1990s, with a consequent improvement in prognosis for people with rectal cancer and reduction in the risk of local recurrence.

"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer," says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery. "Thanks to our results, radiotherapy is recommended to many rectal cancer patients."

However, radiotherapy can cause adverse reactions and the optimal radiotherapeutic method and the interval between it and the ensuing surgery have been mooted.

The study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery. These hypotheses have now been tested in a study in which rectal cancer patients were randomly assigned to three different treatment arms:

The results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes. It also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.

"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients," says Professor Martling. "The results can now be immediately put to clinical use to the considerable benefit of the patients."

Explore further: Specialists make breakthrough for bowel cancer patients

More information: Johan Erlandsson et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial, The Lancet Oncology (2017). DOI: 10.1016/S1470-2045(17)30086-4

Specialists at The Christie and The University of Manchester have made a breakthrough which will spare patients with cancer of the lower bowel, rectal cancer, from major surgery.

(HealthDay)There are no statistically significant differences in the rates of local recurrence (LR), distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with short-course (SC) ...

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow-up show that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)-radiotherapy for patients with cT3-resectable ...

Some older women with breast cancer could safely avoid radiotherapy, without harming their chances of survival, a study has shown.

(HealthDay)Patients with localized rectal cancer may achieve similar survival rates by having minimally invasive laparoscopic surgery, instead of more invasive open surgery, according to new research published in the April ...

A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's attack on tumors back into the kind that amplify it. This is the finding of a study led ...

Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one ...

(Medical Xpress)A team of researchers affiliated with multiple institutions in Korea has found that genetically altering a type of bacteria and injecting it into cancerous mice resulted in the disappearance of tumors in ...

Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell type and also found therapies capable of thwarting those cells when the gatekeeper ...

A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant ...

Studies abound that point to a role for plain old aspirin in keeping deadly cancers at bay. While aspirin is not yet part of mainstream treatment for any cancer, it is recommended by the U.S. Preventive Services Task Force ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:

New method reduces adverse effects of rectal cancer treatment - Medical Xpress